Genmab A/S

It has been a tough month for Genmab, with Johnson & Johnson opting out of a pact and a lawsuit landing from AbbVie, but the Danish biotech has come out fighting with the announcement of a new sha

Who: Roche and Oxford BioTherapeutics What: The Swiss major has entered into a multi-year collaboration with OBT to develop first-in-class antibody-based therapeutics for the treatment of cancer.

The pressure on Genmab to deliver positive results from its late-stage development programs has intensified now that the most closely watched event on the company’s 2025 calendar has arrived and the r

Biopharma merger and acquisition value for the fourth quarter of 2024 reached $9.4bn from 34 transactions, 15 of which had disclosed values. At the top was H. Lundbeck’s $2.6bn purchase of publicly tr